International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study.
A multicenter study was sponsored by the International Atomic Energy Agency (IAEA) to assess the safety and efficacy of transarterial rhenium-188 ((188)Re) HDD lipiodol (radioconjugate to lipiodol using an HDD kit) in the treatment of unresectable hepatocellular carcinoma. During 5 years, 185 patients received at least 1 treatment of radioconjugate, and 51 were retreated. The level of radioconjugate administered was based on radiation-absorbed dose to critical normal organs, calculated after a "scout" dose of radioconjugate. The total injected activity, including the scout dose during the first treatment, ranged from 21 to 364 mCi (mean, 108 mCi/4 GBq). Immediate and late side-effects were minimal. Tumor size could be evaluated in 88 patients. Among these patients, the objective response rate was 25%; stable disease was observed in 53% and tumor progression in 22%. With a median follow-up of 455 days, the estimated 12- and 24-month overall survival was 46% and 23%. This multicenter study shows that (188)Re lipiodol is a safe and cost-effective method to treat primary hepatocellular carcinoma via the transarterial route and requires further evaluation by treatment of greater numbers of patients.
Bernal
Patricia
P
Fundacion Santa Fe de Bogota, Bogota, Colombia.
Raoul
Jean-Luc
JL
Stare
Janez
J
Sereegotov
Erdenechimeg
E
Sundram
Felix X
FX
Kumar
Ajay
A
Jeong
Jae-Min
JM
Pusuwan
Pawana
P
Divgi
Chaitanya
C
Zanzonico
Pat
P
Vidmar
Gaj
G
Buscombe
John
J
Chau
Trinh Thi Minh
TT
Saw
Maung Maung
MM
Chen
Shaoliang
S
Ogbac
Ruben
R
Dondi
Maurizio
M
Padhy
Ajit Kumar
AK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007269:Injections, Intra-Arterial; D007390:International Agencies; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009678:Nuclear Energy; D011379:Prognosis; D011868:Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D011880:Radiotherapy Planning, Computer-Assisted; D012211:Rhenium / Q000008:administration & dosage* / Q000627:therapeutic use
D011868:Radioisotopes; D012211:Rhenium; D007459:Iodized Oil